NSE/DIVISLAB

DIVISLABDivi's Laboratories Ltd

Healthcare · NSE

₹6,229-1.02%

52-wk low52-WEEK RANGE52-wk high

₹5,386.15+15.6% from low ·-10.8% from high₹6,983.5

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

DIVISLAB+15.65% · 1Y

Range high ₹7,071.5Range low ₹5,231.6Latest ₹6,229252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareDrug Manufacturers - Specialty & GenericLargecapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite13/100

Performance

Low

Hasn't fared well — amongst the weak performers.

· 52w return +5.7%
· Below 200-DMA (-0.0%) — downtrend

Valuation

High

Looks expensive vs the sector.

· P/E 67.2 — 78% above sector median 37.8
· P/B 10.81 above sector median

Growth

Low

Lagging the market in growth.

· Revenue YoY +12.3%
· Profit YoY -1.0% — earnings slipping

Profitability

Medium

Average profitability vs peers.

· ROE 16.1%
· Net margin 23.4% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeC(56/100)

Durability

A+

91/100

Financially resilient — strong quality + solvency profile.

Show 4 drivers

Piotroski F-score8/9 (89pt)
Altman Z" score8.99 (100pt)
Debt/Equity0.01 (100pt)
ROE16.1% (64pt)

Valuation

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 4

Lean balance sheet (D/E 0.01)
Low leverage means earnings are less sensitive to rate cycles
Strong net margin (23.4%)
High margin indicates pricing power + operating efficiency
Financial quality score 8/9
Piotroski ≥7 historically associated with outperformance
Bankruptcy risk low (Altman Z″ 8.99)
Z″ above 2.60 sits squarely in the 'safe' zone

WEAKNESSES · 1

Premium to sector on P/E (+78%)
P/E 67.2 vs Healthcare median 37.8

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 1

Valuation compression risk
P/E 67.2 is 78% above sector — any growth miss gets punished

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

-1.0%

+1.8%

+2.6%

-5.6%

+9.1%

+15.6%

+30.2%

+11.9%

10Y

+18.1%

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
DIVISLABTHIS Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%
ALKEM Alkem Laboratories Limited	₹5,582	+11.6%	67,578	28.5	5.06	17.8%	0.17	+2.3%

ASK AXEL

Dig deeper into DIVISLAB

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for DIVISLAB — all in one sourced reply.

Ask free in chat

Run these tools on DIVISLAB

Historical return →

"If I had bought DIVISLAB in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on DIVISLAB

Brokerage + charges →

All-in cost for trading DIVISLAB

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	23.28	24.07	+3.4%
-2q	22.21	25.97	+16.9%
-3q	22.43	20.49	-8.7%
-4q	22.20	24.93	+12.3%

Date	Amount
2025-07-25	₹30.00
2024-08-02	₹30.00
2023-08-11	₹30.00
2022-08-11	₹30.00
2021-08-17	₹20.00
2020-02-25	₹16.00
2019-08-14	₹16.00
2018-08-31	₹10.00
2017-09-15	₹10.00

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.244	×6.56	1.599
Retained Earnings / Total Assets (B)	0.747	×3.26	2.435
EBIT / Total Assets (C)	0.267	×6.72	1.796
Book Equity / Total Liabilities (D)	3.013	×1.05	3.164

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q4
Revenue	2,338	2,319	2,550	2,410	2,604
Operating profit	617	644	784	617	772
OPM %	26.4%	27.8%	30.8%	25.6%	29.6%
Interest	1	—	1	3	6
PBT	722	726	864	733	780
Tax %	29.4%	18.9%	23.4%	25.6%	25.3%
Net profit	510	589	662	545	583
EPS (₹)	19.20	22.20	—	20.49	21.98

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	8,799	7,665	7,796	9,325
Operating profit	3,574	2,027	1,832	2,571
OPM %	40.6%	26.4%	23.5%	27.6%
Interest	0	—	3	2
Depreciation	308	339	375	399
PBT	3,684	2,369	2,163	2,916
Tax %	19.6%	23.0%	26.0%	24.9%
Net profit	2,960	1,824	1,600	2,191
EPS (₹)	111.52	68.69	60.27	82.53

DIVISLABDivi's Laboratories Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

SWOT analysis

Fundamentals

Peer comparison · Healthcare

Ask Axel about DIVISLAB

Recent news

Dig deeper into DIVISLAB

Run these tools on DIVISLAB

Technical snapshot

Earnings history + surprises

Dividends + splits history

Stock scorecard

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Fundamentals

Valuation positioning

Monthly seasonality

Monthly return distribution

Recent news

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	53	53	53	53
Reserves	9,989	10,959	11,786	13,400
Borrowings	4	4	3	4
Total liabilities	13,375	14,439	15,470	16,932

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	1,912	2,459	1,261	1,653
CF Investing	-2,195	-2,707	-269	-804
CF Financing	-532	-797	-799	-799
Net cash flow	-816	-1,045	193	50

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	27.6%	23.5%	26.4%	40.6%
Net margin %	23.5%	20.5%	23.8%	33.6%
ROE %	17.3%	14.0%	17.3%	29.5%
ROCE %	23.1%	19.0%	19.2%	36.7%
Debt / Equity	0.00	0.00	0.00	0.00
Dividend payout %	36%	50%	44%	18%
Interest coverage	1459.0×	722.0×	—	9956.4×
Revenue growth YoY	+19.6%	+1.7%	-12.9%	—
Profit growth YoY	+36.9%	-12.3%	-38.4%	—